Daratumumab interference with immunohematology testing in a nonmultiple myeloma neutropenic patient, in need of granulocyte transfusion

Abstract

Daratumumab (DARA) may interfere with immunohematology tests by binding to endogenous CD38 present on the surface of the red blood cells. DARA was Food and Drug Administration approved for refractory multiple myeloma patients, but now its application is being explored in other oncology patients also. The disease condition of the patient does not change the process of resolution of incompatible cross-matches, and blood transfusion services (BTS) must be vigilant about the drug but not the diagnosis. Effective communication between BTS and oncology departments is crucial in the timely resolution of DARA interferences. All BTS must have standard operating procedures in place for such discrepancies.

Keywords

• anti-cd38
• compatibility testing
• daratumumab
• dithiothreitol
• serology interference